- 1 Association between angiotensin-converting enzyme inhibitors and angiotensin II
- 2 receptor blockers use and the risk of infection and clinical outcome of COVID-19: a
- 3 comprehensive systematic review and meta-analysis.
- 4 Guangbo Qu, MD^{1a}, Liqin Shu, MD^{2a}, Evelyn J. Song, MD³, Dhiran Verghese, MD⁴, John
- 5 Patrick Uy, MD⁴, Ce Cheng, DO⁵, Qin Zhou, PhD⁶, Hongru Yang MD⁷, Zhichun Guo MD⁷,
- 6 Mengshi Chen, MD⁸, Chenyu Sun, MD, MSc^{4,*}
- 7 1. Department of Epidemiology and Health Statistics, School of Public Health, Anhui
- 8 Medical University, No. 81 Meishan Road, Hefei 230032, Anhui, China.
- 9 2. Department of Child Health care, Maternal and Child Health Care Hospital of Anhui
- 10 Province (Affiliated Maternal and Child Health Care Hospital of Anhui Medical University),
- Hefei 230001, Anhui, China.
- 3. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD,
- 13 USA.
- 4. AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, 60657,
- 15 Illinois, USA
- 5. Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville 28304,
- 17 NC, USA
- 18 6. Mayo Clinic, Rochester, MN 55905, USA
- 19 7. Massachusetts College of Pharmacy and Health Science, 179 Longwood Ave, Boston,
- 20 02115, MA, USA
- 8. Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public
- 22 Health, Central South University.
- a. Guangbo Qu and Liqin Shu contributed equally to this study and should be considered as
- 24 co-joint first authors.
- 25 *Correspondence to: Chenyu Sun, Internal Medicine, AMITA Health Saint Joseph Hospital
- 26 Chicago, Lake Shore Drive Chicago, Illinois 60657, Chicago, USA. E-mail:
- 27 drsunchenyu@yeah.net.
- Short title: ACEIs and ARBs use and COVID-19 risk

Abstract

1

Background The effect of using Angiotensin-converting enzyme inhibitors (ACEIs) and
 Angiotensin-receptor blockers (ARBs) on the risk of coronavirus disease 2019 (COVID-19)

4 is a topic of recent debate. Although studies have examined the potential association between

5 them, the results remain controversial. This study aims to determine the true effect of

6 ACEI/ARBs use on the risk of infection and clinical outcome of COVID-19.

7 Methods Five electronic databases (PubMed, Web of science, Cochrane library, China

8 National Knowledge Infrastructure database, medRxiv preprint server) were retrieved to find

9 eligible studies. Meta-analysis was performed to examine the association between

ACEI/ARBs use and the risk of infection and clinical outcome of COVID-19.

11 Results 22 articles containing 157,328 patients were included. Use of ACEI/ARBs was not

associated with increased risk of infection (Adjusted OR: 0.96, 95% CI: 0.91-1.01, $I^2=5.8\%$)

or increased severity (Adjusted OR: 0.90, 95% CI: 0.77-1.05, I^2 =27.6%) of COVID-19. The

use of ACEI/ARBs was associated with lower risk of death from COVID-19 (Adjusted OR:

15 0.66, 95% CI: 0.44-0.99, I^2 =57.9%). Similar results of reduced risk of death were also found

for ACEI/ARB use in COVID-19 patients with hypertension (Adjusted OR: 0.36, 95% CI:

17 0.17-0.77, $I^2=0$).

18 Conclusion This study provides evidence that ACEI/ARBs use for COVID-19 patients does

19 not lead to harmful outcomes and may even provide a beneficial role and decrease mortality

20 from COVID-19. Clinicians should not discontinue ACEI/ARBs for patients diagnosed with

21 COVID-19 if they are already on these agents.

Keywords: COVID-19; Angiotensin-converting enzyme inhibitor; Angiotensin-receptor 1

2 blockers; risk; systematic review; meta-analysis.

1. Introduction

3

4

21

5 In December 2019, the first case of novel coronavirus disease (COVID-19) caused by 6 7 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, 8 China [1, 2]. Due to the rapidly increasing number of cases worldwide, on March 11, 2020, 9 the World Health Organization (WHO) declared the COVID-19 outbreak a global pandemic As of June 3, 2020, there were 6, 287, 771 confirmed cases and 379, 941 deaths globally per 10 11 WHO [3]. COVID-19 has greatly impacted both professional and personal lives of everyone 12 worldwide. The epidemiological and clinical characteristics of COVID-19 have been well described 13 in previous studies [4, 5]. Hypertension, diabetes and cardiovascular diseases (CVD) 14 15 including congestive heart failure (CHF) and myocardial infarction are common 16 comorbidities reported in patients with COVID-19 and have been associated with a poor 17 prognosis [5, 6]. Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin-receptor blockers (ARBs) are first line anti-hypertensive medications and are 18 included in the guideline-directed therapy for diabetic nephropathy, CHF and myocardial 19 20 infarction. Angiotensin-converting enzyme 2 (ACE2), a membrane-bound aminopeptidase, is

widely expressed in certain tissues of human body including lung, intestine, heart, and

4 kidneys, and it has been shown that the use of ACEIs and ARBs can increase the expression 1 2 of ACE2 [7, 8]. Furthermore, ACE2 acts as a functional receptor and SARS-CoV-2 utilizes the ACE2 for attachment of its spike protein, in the process of its entrance into cells [9,10]. 3 4 These findings led some investigators to hypothesize that the use of ACEIs or ARBs may 5 increase the risk of infection by SARS-CoV-2 and the severity of COVID-19 [11-13]. Several clinical studies have been conducted to test this hypothesis. However, a 6 7 consensus has not been reached regarding how the use of ACEIs or ARBs affects the outcome 8 of patients with COVID-19. The goal of this meta-analysis is to clarify the effects of ACEIs 9 and/or ARBs on the infection risk, severity, and mortality of COVID-19, hoping to shed more 10 light in the prevention and treatment of the current ongoing pandemic. 11 2. Methods 12 13 This study was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14]. 14 15 2.1 Literature search and data source 16 17 We searched five electronic databases (PubMed, Web of science, Cochrane library, China National Knowledge Infrastructure database, medRxiv preprint server) to collect 18 19 relevant studies published until May 20, 2020. The search strategy was established and 20 performed by authors. The search terms used included following: two

(angiotensin-converting-enzyme inhibitor OR ACEI OR angiotensin-receptor blockers OR

1 ARB) AND (coronavirus OR COVID-19 OR SARS-CoV-2). There was no language

limitation on the search. All references of included studies were evaluated for additional

studies to include as many eligible studies as possible. For retrieved records, we used

reference management software (NoteExpress, college version) to save and filter.

2.2 Study selection

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

First, we reviewed the title and abstract of retrieved studies and excluded irrelevant ones. Then, we read through the full-text of remaining studies and included eligible studies based on our inclusion and exclusion criteria. Our inclusion criteria are as follows: (1) participants were patients diagnosed with COVID-19; (2) patients were reported as having ACEI and/or ARB exposure and non-ACEI and/or ARB exposure (ACEI use versus non-ACEI use; ARB use versus non-ARB use; ACEI/ARB use versus non-ACEIARB use); (3) at least one of following outcomes of COVID-19 was reported: positive rate/infection rate, hospital admission rate, severity, mortality in groups of ACEI and/or ARB exposure and non-ACEI and/or ARB exposure or the association between ACEI and/or ARB exposure and the risk of infection, hospital admission, severity, and death due to COVID-19; (4) the study design was case-control or cohort. Exclusion criteria are as follows: (1) the studies were reviews, case-reports, or animal experiments; (2) studies did not meet the inclusion criteria; (4) The data of interest was not reported; (4) no clear definition or diagnose methods of COVID-19. Two authors (Guangbo Qu and Liqin Shu) conducted the selections independently, and any disagreement was solved through discussion.

2.3 Data extraction and quality assessment

Following information was extracted using a standard chart form: first author's name, number of patients, number of patients in ACEI/ARB exposure (only ACEI exposure, only ARB exposure, either ACEI or ARB exposure) and non-exposure groups, patients' characteristics, infection risk, hospital admission, severity, and mortality of patients in each group, odds ratios (ORs) or risk ratios (RRs) or hazard ratio (HRs) of the infection, hospital admission, severity, and mortality of COVID-19.

Considering that the included studies were observational studies, the Newcastle-Ottawa Scale (NOS) was used to assess the quality from three aspects: (1) selection of participants; (2) comparability of groups; (3) assessment of exposure and outcome [15]. NOS contained eight items with scores ranging from 0 to 9 stars. The quality of studies was divided into three categories based on the scores: low quality is 0-3 stars, moderate quality is 4-5 stars, and high quality is 6 stars or above. Two authors (Guangbo Qu and Liqin Shu) assessed quality

3. Statistical analysis

Meta-analyses were conducted to assess for associations. Crude and adjusted odds ratios (Crude OR and Adjusted OR), with corresponding 95% confidence intervals, were calculated using the extracted binary data or effect sizes that was reported in all studies. Additionally, if available, Crude OR and/or Adjusted OR were also calculated to explore the association

independently, and disagreement was resolved by consensus.

between ACEI/ARB use and outcomes of COVID-19 among patients with hypertension. The 1 2 statistical heterogeneity between studies was identified using the Cochrane's Q test and I-square test. Heterogeneity was present if P value of Q test was less than 0.1 or the value of 3 I² was more than 50% [16]. The model for meta-analyses was chosen based on the level of 4 5 heterogeneity between studies; if obvious heterogeneity was present, then random-effects model was used, otherwise, the fix-effects model was used [17]. Subgroup analysis was 6 7 conducted based on the characteristics of included studies. Publication bias was identified via Begg's and Egger's tests. If P value of Begg's and Egger's tests were more than 0.05, then 8 9 publication bias is present. Sensitivity analysis was performed by omitting studies one by one to assess the stability of pooled results. All statistical analyses were performed using STATA 10

4. Results

11

12

13

14

15

16

17

18

19

20

21

4.1 Characteristics of included studies

software (version 14.0) and Review Manager (version 5.3).

After initial search, 477 records were retrieved (PubMed: n=166, Web of science: n=228, Cochrane library: n=9, China National Knowledge Infrastructure database: n=27, medRxiv preprint server: n=41, Other sources: n=6). 27 records were excluded for duplication. After reading the titles and abstracts, 391 records were excluded due to irrelevance. After study selection according to the inclusion and exclusion criteria, 36 articles were excluded and one study was further excluded because it was retracted by the journal. Finally, 22 articles containing 157,328 patients were included in this meta-analysis [8, 10, 18-37]. The flow chart

of the selection process is displayed in Figure 1.

The characteristics of included studies were shown in Table 1. Of included studies, 11 were conducted in China [8,16,20,21,22,24,25,27,33,35,36], six were from the United States [19,23,29,32,34,37], two were from Italy [10,30], one from Spain [26], one from United Kingdom [28], and one from Belgium [31]. All, but three, were cohort studies. The sample size of each study ranged from 42 to 37,031. Multiple comorbidities were reported and all patients in eight of the studies had hypertension [8,18,22,25,27,32,33,37]. Majority of the studies were high quality studies. Detailed quality assessment results are in Table S1.

4.2 ACEI/ARB use and COVID-19 infection

9

10

11 Pooled meta-analyses showed that, without adjusting for any confounders, ACEI, ARB, and ACEI/ARB use were not significantly associated with the risk of COVID-19 infection 12 (Crude OR: 1.27, 95% CI: 0.95-1.69 for ACEI use; Crude OR: 1.07, 95% CI: 0.76-1.50 for 13 ABR use; Crude OR: 1.10, 95% CI: 0.84-1.43 for ACEI/ARB use); however, obvious 14 heterogeneity was present between studies (All I² >50%) (Table 2, Figure 2). Similarly, after 15 16 adjusting for confounders, ACEI, ARB, and ACEI/ARB use were not significantly associated with the risk of COVID-19 infection (Adjusted OR: 0.94, 95% CI: 0.87-1.01, I²=0 for ACEI 17 use; Adjusted OR: 0.73, 95% CI: 0.49-1.09, I²=95.1% for ABR use; Adjusted OR: 0.96, 95% 18 CI: 0.91-1.01, I²=5.8% for ACEI/ARB use). Furthermore, subgroup analysis based on 19 20 different characteristics of studies showed no correlation between the use of ACEI and/or ARB and risk of COVID-19 infection. 21

4.3 ACEI/ARB use and hospital admission for COVID-19

Pooled meta-analyses showed that patients using ACEI, ARB, and ACEI/ARB had

higher risk of hospital admission for COVID-19 compared to patients not using these

medications (Adjusted OR: 1.29, 95% CI: 1.07-1.57, I²=62.4% for ACEI use; Adjusted OR:

6 1.69, 95% CI: 1.46-1.96, I²=0 for ABR use; Adjusted OR: 1.38, 95% CI: 1.21-1.57, I²=34.5%

7 for ACEI/ARB use) (Table 2 and Figure 3).

1

2

4

5

8

9

11

12

13

14

15

16

17

18

19

20

21

4.4 ACEI/ARB use and severity of COVID-19

Use of ACEI, ARB, and ACEI/ARB was not associated with severity of COVID-19

infection for both pooled crude and adjusted OR (Adjusted OR: 0.90, 95% CI: 0.72-1.14,

I²=0 for ACEI use; Adjusted OR: 0.91, 95% CI: 0.74-1.13, I²=45.8% for ABR use; Adjusted

OR: 0.90, 95% CI: 0.77-1.05, $I^2=27.6\%$ for ACEI/ARB use). Additionally, subgroup analysis

based on different characteristics (study design, region, race, study quality) also did not show

any significant association (Table 2 and Figure 4). Furthermore, for patients with

hypertension, ACEI, ARB, and ACEI/ARB use was not significantly associated with severity

of COVID-19 infection (Table S2).

4.5 ACEI/ARB use and COVID-19 related mortality

Only one study reported the association between ACEI and ARB use and risk of death

from COVID-19 without adjusting confounders separately (OR: 0.91, 95% CI: 0.38-2.17 for

ACEI use; OR: 0.77, 95% CI: 0.41-1.43 for ABR use) [18]. Only one study reported no 1 significant association between ACEI use and risk of death from COVID-19 (OR: 0.97, 95% 2 CI: 0.69-1.34) [30]. The pooled crude OR showed no significant association between 3 ACEI/ARB use and risk of death from COVID-19 (Crude OR: 0.88, 95% CI: 0.66-1.18, 4 5 I²=60.9%). However, the pooled adjusted ORs showed that patients on ACEI/ARB had a lower risk of death from COVID-19 (Adjusted OR: 0.66, 95% CI: 0.44-0.99, I^2 =57.9%). No 6 study reported the association between ARB use and the risk of death from COVID-19 (Table 7 2 and Figure 5). Furthermore, subgroup analysis on studies from China or studies of Asian 8 9 population found that ACEI/ARB use was associated with a lower risk of death from COVID-19. For patients with hypertension, ACEI/ARB use also was associated with a lower 10 11 risk of death from COVID-19 (Adjusted OR: 0.36, 95% CI: 0.17-0.77, I²=0) (Table S3). 12 4.6 Publication bias and results of sensitivity analysis 13 There was no significant publication bias among meta-analyses with two or more studies 14 included (All P values were more than 0.05) based on Begg's and Egger's tests (Table S4). 15 16 Sensitivity analysis showed that no study had significant impact on the stability of pooled 17 results from meta-analyses. 18 5. Discussion 19 The effect of ACEI/ARB use on COVID-19 patients has been a controversial topic since 20 the beginning of this pandemic. Based on prior studies on the effect of ACEI/ARBs on ACE2 21

expression [7, 38, 39], it was initially hypothesized that increased expression of ACE2 from 1 2 ACEI/ARB may increase the risk of SARS-COV-2 entrance into respiratory epithelial cells through binding to the structural transmembrane ACE2 receptor. Therefore, ACEI/ARB may 3 4 theoretically increase the susceptibility of infection and lead to worse outcomes from 5 COVID-19 [11, 40]. However, even though elevated expression of ACE2 caused by 6 ACEI/ARB use has been found in animal studies [7, 38, 39], no evidence has indicated 7 similar effects in human studies. Many studies have been published in the recent months 8 attempting to better understand the effects of ACEI/ARB in COVID-19 patients [8, 10, 19, 29, 9 30]. Our systematic review and meta-analysis shows that ACEI/ARBs use is not significantly 10 associated with increased infection risk and severity of COVID-19 and is actually associated 11 with a decreased risk of death from COVID-19. However, it does lead to an increased risk of 12 hospital admissions. The increased risk of hospitalization admissions in patients on 13 14 ACEI/ARB should be interpreted with caution because in the included studies, residual 15 confounding factors such as comorbidities like CVD were not well adjusted for [19, 30]. 16 Patients who are taking ACEI/ARB likely have underlying cardiovascular comorbidities and 17 prior studies demonstrated that patient comorbidities including hypertension and CVD are associated with severe COVID-19 infections, requiring hospitalization, and increased 18 mortality [41, 42]. Therefore, additional large, prospective, randomized studies are needed to 19 20 better characterize the effect of ACEI/ARB use on rate of hospitalization of COVID-19 patients. 21

Interestingly, the pooled crude ORs did not show significant association between 1 2 ACEI/ARB use and the risk of death from COVID-19, but after pooling the adjusted ORs, ACEI/ARB use was associated with a decreased risk of death from COVID-19 in all patients 3 and in those with hypertension. However, the crude OR did not found a significant 4 5 association of ACEI use and the risk of death from COVID-19. This difference seen bet the crude and adjusted ORs is likely because some important confounders were adjusted for 6 7 adjusted ORs, which may reflect the true association between ACEI/ARB use and risk of 8 death from COVID-19. Additionally, none of the studies reported the association between 9 ARB use and risk of death from COVID-19; therefore, pooled adjusted OR for ARBs was not calculated. 10 ACEI/ARBs are commonly used in the treatment of hypertension and CHF to inhibit 11 Angiotensin II and downregulate the Renin-angiotensin-aldosterone system (RAAS) [43]. 12 13 The decreased risk of death is likely due to continued management of patients' existing 14 underlying diseases as poorly controlled hypertension and CHF are both associated with worse outcomes in COVID-19 patients [44]. Additionally, the anti-inflammatory and 15 immune-modulatory properties of ACEI/ARBs may also explain their protective effect. 16 17 Heightened inflammatory response is an important factor leading to adverse outcomes of COVID-19 patients [45]. Previously, it has been shown that Angiotensin II increases 18 expression of inflammatory cytokines via activation of Angiotensin II receptor type 1 (AT1R) 19 20 [46]. ACEI/ARB decreases the level of Angiotensin II, potentially attenuating the inflammatory response. Additionally, ACEI/ARB reduces T-cell depletion in peripheral blood 21

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

13

and inhibits dendritic cell maturation and Th1 and Th17 cell polarization, resulting in a more potent immune system [47]. This hypothesis is supported in the study by Meng et al, in which it was demonstrated that ACEI/ARB use in COVID-19 patients was associated with lower IL-6 level, increased CD3 and CD8 T-cell counts, and decreased peak viral load [25]. This systemic review and meta-analysis comprehensively explored the effect of ACEI/ARB use on infection risk and different clinical outcomes related to COVID-19. Our study is consistent with results from prior studies on this topic, where they also demonstrated that ACEI/ARB use does not increase the severity of COVID-19 infection and decreases mortality [48-50]. Additionally, we also included information not available in previous systemic reviews such as the association between ACEI/ARB use and hospitalization due to COVID-19. This study helps to shed light into the current debate on the use of ACEI/ARBs in patients with COVID-19 and demonstrates that ACEI/ARB use does not lead to increased risk of COVID-19 infection and may even decrease the risk of death from COVID-19. The results from this study supports the joint statement from American Heart Association (AHA), Heart Failure Society of America (HFSA) and American College of Cardiology (ACC) and the statement from the European Society of Cardiology (ESC) Council on Hypertension that patients with COVID-19 taking ACEI/ARBs should continue their treatment [51]. A few limitations present in our study should be noted. First, all the studies included are observational studies, making it difficult to infer accurate causation. Second, no data was provided regarding the dose and exposure duration of ACEI/ARBs; therefore, we could not

determinate whether COVID-19 infection is affected by the dose and duration of ACEI/ARBs

exposure. Third, beta blockers can also prevent ACE2 activity [52], therefore, the effect of

14

ACEI/ARB use may be underestimated for patients with CVD who also take beta blockers.

Finally, given that some important confounders (such as comorbidities) have not been

adjusted for in the included studies, the true association between ACEI/ARB use and the risk

of hospitalization could not be well inferred.

Conclusion

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

In conclusion, ACEI/ARB use does not affect the risk and severity of COVID-19

infection and actually leads to a decreased mortality from COVID-19. The effect of

ACEI/ARB use on hospitalization needs to be further assessed with adjusting for potential

confounders. The potential protective role of ACEI/ARB supports the recommendation that

these agents should not be discontinued for COVID-19 patients if they are already on them.

6. Acknowledgements

Guangbo Qu and Chenyu Sun contributed to the study design, the development of

research protocol, and supervision of whole steps of this study. Liqin Shu designed the search

strategy and conducted the literature search. Guangbo Qu and Liqin Shu conducted study

selection, data extraction and quality assessment of included studies. Chenyu Sun checked the

literature search and data extraction. Guangbo Qu performed data analyses and created tables

and figures. Guangbo Qu and Chenyu Sun took responsibility for the interpretation of results.

Guangbo Qu wrote the first draft of manuscript. Liqin Shu, Evelyn J. Song, Ce Cheng,

- 1 Dhiran Verghese, John Patrick Uy, Qin Zhou, Hongru Yang, Zhichun Guo, Chenyu Sun
- 2 contributed to the edition and revision of the draft of manuscript. All authors reviewed and
- 3 approved final version of the manuscript.
- 4 .

5

9

12

13

6 7. Funding

- 7 This study is financially supported by Hunan Provincial Key Laboratory of Clinical
- 8 Epidemiology. (2020ZNDXLCL002)

10 8. Disclosure of interest

The authors have no interest to disclosure.

Reference

- 14 [1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
- Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus
- Investigating and Research Team. A novel coronavirus from patients with pneumonia in
- 17 China, 2019. N Engl J Med 2020; 382: 727-733.
- 18 [2] Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J
- 19 *Physiol Endocrinol Metab* 2020; 318: E736-E741.
- 20 [3] World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report –
- 135. Geneva, Switzerland: World Health Organization; June 3, 2020. Available online:

- 1 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200603-covid
- 2 -19-sitrep-135.pdf?sfvrsn=39972feb_2
- 3 [4] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T,
- 4 Zhang X, Zhang L. Epidemiological and Clinical Characteristics of 99 Cases of 2019
- Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. *Lancet* 2020; 395:
- 6 507-513.
- 7 [5] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and Impact of
- 8 Cardiovascular Metabolic Diseases on COVID-19 in China. *Clin Res Cardiol* 2020; 109:
- 9 531-538.
- 10 [6] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL,
- Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B,
- 12 Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH,
- Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY,
- 14 Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical
- 15 Treatment Expert Group for COVID-19. Comorbidity and Its Impact on 1590 Patients
- With COVID-19 in China: A Nationwide Analysis. *Eur Respir J* 2020; 55: 2000547.
- 17 [7] Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI,
- Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II
- receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:
- 20 2605-2610.
- 21 [8] Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai JL, Yang R, Han J, Huang Y, He S.

1 Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical

- 2 Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective
- 3 Study. *Hypertension* 2020; 76: 51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143.
- 4 [9] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL,
- 5 Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a
- functional receptor for the SARS coronavirus. *Nature* 2003; 426: 450-454.
- 7 [10] Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone
- 8 System Blockers and the Risk of Covid-19. N Engl J Med 2020 May 1. doi:
- 9 10.1056/NEJMoa2006923. [Epub ahead of print].
- 10 [11] Diaz JH. Hypothesis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin
- 11 Receptor Blockers May Increase the Risk of Severe COVID-19. *J Travel Med* 2020 Mar
- 18. doi: 10.1093/jtm/taaa041. Online ahead of print.
- 13 [12] Fang L, Karakiulakis G, Roth M. Are Patients With Hypertension and Diabetes Mellitus
- at Increased Risk for COVID-19 Infection? *Lancet Respir Med* 2020; 8: e21.
- 15 [13] G O'Mara. Could ACE inhibitors, and particularly ARBs, Increase susceptibility to
- 16 COVID-19 infection? *BMJ* 2020; 368: m406.
- 17 [14] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items
- for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6:
- 19 e1000097.
- 20 [15] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the
- quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; 25: 603-605.

- 2 meta-analyses. *BMJ* 2003; 327: 557-560.
- 3 [17] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;
- 4 21: 1539-1558.
- 5 [18] Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System
- 6 Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for
- 7 Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020
- 8 Apr 23. doi: 10.1001/jamacardio.2020.1624. [Epub ahead of print].
- 9 [19] Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE,
- Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB,
- 11 Chung MK. Association of Use of Angiotensin-Converting Enzyme Inhibitors and
- Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019
- 13 (COVID-19). JAMA Cardiol 2020 May 5. doi: 10.1001/jamacardio.2020.1855. [Epub
- ahead of print].
- 15 [20] Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K,
- Zeng QT. [Clinical characteristics and outcomes of 112 cardiovascular disease patients
- infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48: E004. [Article in
- 18 Chinese]
- 19 [21] Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, Oian J, Yu
- 20 K, Gong H, Ge J. The effect of RAS blockers on the clinical characteristics of
- 21 COVID-19 patients with hypertension. *Ann Transl Med* 2020; 8: 430.

- 1 [22] Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M,
- 2 Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q,
- Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M,
- 4 Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L,
- 5 Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors
- and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension
- 7 Hospitalized With COVID-19. *Circ Res* 2020; 126: 1671-1681.
- 8 [23] Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A,
- 9 Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y,
- Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk
- of Covid-19. N Engl J Med 2020 May 1. doi: 10.1056/NEJMoa2008975. [Epub ahead of
- print].
- 13 [24] Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu
- 14 X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19
- with Different Severity: A Multicenter Study of Clinical Features. *Am J Respir Crit Care*
- *Med* 2020; 201: 1380-1388.
- 17 [25] Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L,
- 28 Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of
- 19 COVID-19 patients with hypertension. *Emerg Microbes Infect* 2020; 9: 757-760.
- 20 [26] de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A,
- Laredo L, Laosa O, Centeno-Soto GA, Gálvez MA, Puerro M, González-Rojano E,

20 1 Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Rodrí guez-Miguel A, Rodríguez-Puyol D, MED-ACE2-COVID19 study group. Use of 2 renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring 3 admission to hospital: a case-population study. Lancet 2020; 395: 1705-1714. 4 5 [27] Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H, Han J, Song W, Huang Q, Chen Z. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center 6 7 retrospective observational medRxiv preprint 2020. doi: study. 10.1101/2020.04.06.20054825. 8 9 [28] Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, Roguski L, Noor K, Shek A, o'gallagher K, Zakeri R, Shah A, Teo J, Dobson RJB. ACE-inhibitors and 10 Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 11 infection in a multi-site UK acute Hospital Trust. medRxiv preprint 2020. doi: 12 13 10.1101/2020.04.07.20056788. [29] Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King Jr JT, Skanderson M, Hauser RG, 14 Schultze A, Jarvis CI, Holodniy M, Re III VL, Akgun KM, Crothers K, Taddei TH, 15 Freiberg MS, Justice AC. Covid-19 Testing, Hospital Admission, and Intensive Care 16 17 Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv preprint 2020. doi: 10.1101/2020.04.09.20059964. 18 [30] Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, The Reggio 19 Emilia COVID-19 Working Group. Characteristics and outcomes of a cohort of 20

SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. medRxiv preprint 2020.

- 2 [31] De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, Dobson R,
- Wynendaele E, Van De Wiele C, Vandaele F, Van Dijck D, Bean D, Fedson D, De
- 4 Spiegeleer B. The effects of ARBs, ACEIs and statins on clinical outcomes of
- 5 COVID-19 infection among nursing home residents. Journal of the American Medical
- 6 Directors Association. 2020. doi: 10.1016/j.jamda.2020.06.018.
- 7 [32] Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer
- 8 SB, Vojta D, Krumholz HM. Association of Angiotensin-Converting Enzyme Inhibitors
- 9 and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in
- Hypertensive Patients with Coronavirus Disease-19. medRxiv preprint 2020. doi:
- 11 10.1101/2020.05.17.20104943.
- 12 [33] Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M, Wang Z, Li X, Zhang S, Ye L, Lv J, Wei J,
- 13 Xie T, Gao H, Xu KF, Wang F, Liu L, Jiang C. Anti-hypertensive Angiotensin II receptor
- blockers associated to mitigation of disease severity in elderly COVID-19 patients.
- *medRxiv preprint* 2020. doi: 10.1101/2020.03.20.20039586.
- 16 [34] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the
- 17 Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD,
- Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J,
- 19 Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM,
- Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics,
- 21 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

- 1 New York City Area. *JAMA* 2020; 323: 2052-2059.
- 2 [35] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z.
- 3 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease
- 4 2019 (COVID-19). *JAMA Cardiol* 2020; e201017.
- 5 [36] Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, Wang H, Tan X, Du J, Jin S,
- 6 Huang K, Jiang F, Zhang S, Zheng N, Hu Y, Cai T, Aithal GP. Role of Drugs Affecting
- 7 the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19:
- 8 A Large Case-Control Study from Zheijang Province, China. *medRxiv preprint* 2020. doi:
- 9 10.1101/2020.04.24.20077875.
- 10 [37] Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, Goldberg SL.
- 11 Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with
- 12 Covid-19. *medRxiv preprint* 2020. doi: 10.1101/2020.04.24.20077388.
- 13 [38] Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression.
- 14 *Curr Hypertens Rep* 2008; 10: 410-414.
- 15 [39] Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination
- Renin-Angiotensin System Blockade and Angiotensin-Converting Enzyme 2 in
- 17 Experimental Myocardial Infarction: Implications for Future Therapeutic Directions.
- 18 *Clin Sci (Lond)* 2012; 123: 649-658.
- 19 [40] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients With COVID-19 Infection
- Taking ACEI/ARB. Curr Cardiol Rep, 202; 22: 31.
- 21 [41] Wang B, Li R, Lu Z, Huang Y. Does Comorbidity Increase the Risk of Patients With

- 2 [42] Mantovani A, Beatrice G, Dalbeni A. Coronavirus Disease 2019 and Prevalence of
- 3 Chronic Liver Disease: A Meta-Analysis. *Liver Int* 2020 Apr 4. doi: 10.1111/liv.14465.
- 4 [43] Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's
- 5 perspective. *Mini Rev Med Chem* 2006; 6: 491-497.
- 6 [44] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection
- 7 Taking ACEI/ARB. Curr Cardiol Rep 2020; 22: 31. doi:10.1007/s11886-020-01291-4.
- 8 [45] Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, Monte AD,
- 9 Bove T, Curcio F, Bassi F, Vita SD, Tascini C. Profiling COVID-19 Pneumonia
- 10 Progressing Into the Cytokine Storm Syndrome: Results From a Single Italian Centre
- 11 Study on Tocilizumab Versus Standard of Care. J Clin Virol 2020; 104444. doi:
- 12 10.1016/j.jcv.2020.104444.
- 13 [46] Wang X, Khaidakov M, Ding Z, Mitra S, Lu J, Liu S, Mehta JL. Cross-talk between
- inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes
- with AT1R and AT2R cDNA. Exp Biol Med 2012; 237: 1394-1401.
- 16 [47] Liu J, Zhang PS, Yu Q, Liu L, Yang Y, Guo FM, Qiu HB. Losartan inhibits conventional
- dendritic cell maturation and Th1 and Th17 polarization responses: Novel mechanisms
- of preventive effects on lipopolysaccharide-induced acute lung injury. *Int J Mol Med*
- 19 2012; 29: 269-276.
- 20 [48] Aref A. Abdulhak B, Kashour T, Noman A, Tlayjeh H, Mohsen A, Al-Mallah MH,
- Tleyjeh IM. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor

Blockers and Outcome of COVID-19: A Systematic Review and Meta-analysis. 1 2 medRxiv preprint 2020. doi: 10.1101/2020.05.06.20093260. [49] Zhang X, Yu J, Pan L, Jiang HY. ACEI/ARB Use and Risk of Infection or Severity or 3 Mortality of COVID-19: A Systematic Review and Meta-analysis. Pharmacol Res 2020 4 5 May 15: 104927. doi: 10.1016/j.phrs.2020.104927. [50] Ghosal S, Mukherjee Jagat J, Sinha B, Gangopadhyay KK. The effect of angiotensin 6 7 converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis. 8 9 medRxiv preprint 2020. doi: 10.1101/2020.04.23.20076661. [51] American Heart Association (AHA), Heart Failure Society of America (HFSA) and 10 11 American College of Cardiology (ACC). Patients taking ACE-i and ARBs who contract 12 COVID-19 should continue treatment, unless otherwise advised by their physician. 2020. 13 [52] Wang Y, Moreira Mda C, Heringer-Walther S, Schultheiss HP, Siems WE, Wessel N, 14 Walther T. Beta blockers prevent correlation of plasma ACE2 activity with 15 echocardiographic parameters in patients with idiopathic dilated cardiomyopathy. J 16 17 Cardiovasc Pharmacol 2015; 65: 8-12. 18 19 20

Figure legends

1

21

2 Figure 1. Flow diagram of study selection for this systematic review and meta-analysis. Figure 2. Pooled results of meta-analyses for the association between ACEI/ARB use and risk 3 4 of COVID-19 infection. (A) Pooled crude OR for the comparison between ACEI use versus 5 non-ACEI use; (B) Pooled crude OR for the comparison between ARB use versus non-ARB use; (C) Pooled crude OR for the comparison between ACEI/ARB use versus 6 7 non-ACEI/ARB use; (D) Pooled adjusted OR for the comparison between ACEI use versus 8 non-ACEI use; (E) Pooled adjusted OR for the comparison between ARB use versus 9 non-ARB use; (F) Pooled adjusted OR for the comparison between ACEI/ARB use versus 10 non-ACEI/ARB use. 11 Figure 3. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of hospital admission for COVID-19. (A) Pooled adjusted OR for the comparison between 12 13 ACEI use versus non-ACEI use; (B) Pooled adjusted OR for the comparison between ARB 14 use versus non-ARB use; (C) Pooled adjusted OR for the comparison between ACEI/ARB 15 use versus non-ACEI/ARB use. Figure 4. Pooled results of meta-analyses for the association between ACEI/ARB use and risk 16 17 of severity of COVID-19 infection. (A) Pooled crude OR for the comparison between ACEI use versus non-ACEI use; (B) Pooled crude OR for the comparison between ARB use versus 18 19 non-ARB use; (C) Pooled crude OR for the comparison between ACEI/ARB use versus 20 non-ACEI/ARB use; (D) Pooled adjusted OR for the comparison between ACEI use versus

non-ACEI use; (E) Pooled adjusted OR for the comparison between ARB use versus

non-ARB use; (F) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use. Figure 5. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of death from COVID-19. (A) Pooled crude OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use; (B) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use. **Tables** Table 1. Characteristics of included studies. Table 2. Meta-analysis on the association between ACEI/ARB use and risk of infection, hospital admission, severity, and death of COVID-19.

Table 1. Characteristics of included studies.

| First author | Year | Region | Race | Study design | Total | ACEI/ARB exposure | Non-ACEI/ARB exposure | Age (years) | Male/Female | Diagnostic criteria of COVID-19 | Comorbidity | Comparison groups | Reported association outcome | Quality |
|-----------------|------|------------------|-------|-------------------------|--------|-------------------|-----------------------|-----------------------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|------------------------------|----------|
| LiJ[18] | 2020 | China | Asian | Retrospective cohort | 362 | 115 | 247 | 66.0 (59.0-73.0) | | The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition). | Hypertension (100%); Cerebrovascular disease (18.8%); Coronary heart disease(17.1%); Heart failure(2.8%); Diabetes (35.1%); Digestive disorder(21.5%); Respiratory disease(5.0%); Neurological disease(10.5%); Solid tumor(3.0%); Chronic renal disease(9.7%) | ACEI vs Non-ACEI; ARB vs Non-ARB; ACEI vs Other drugs; ARB vs Other drugs ACEI vs ARB ACEI vs ARB | Severity and death risk | Moderate |
| Mehta N[19] | 2020 | United States | Mixed | Retrospective cohort | 18,472 | 2,285 | 16,187 | 49±21 | 7384/12725 | Laboratory testing using RT-PCR | Diabetes(n=86); Coronary artery disease(n=58); Hypertension (n=186); Chronic obstructive pulmonary disease (n=46); Heart failure (n=52) | ACEI vs Non–ACEI; ARB vs Non–ARB; ACEI/ARB vs Non–ACEI/ARB | Infection and death risk | Moderate |
| Peng YD [20] | 2020 | China | Asian | Retrospective cohort | 112 | 22 | 90 | 62.0 (55.0-67.0) | | The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition). | Hypertension (82.1%);Coronary heart disease (55.4%); Heart failure (35.7%); Diabetse (20.5%) | ACEI/ARB vs Non–ACEI/ARB | Death risk | Moderate |
| Huang Z | 2020 | China | Asian | Retrospective cohort | 50 | 20 | 30 | 52.65±13.12 for ACEI/ARB exposure; 67.77±12.84 for Non-ACEI/ARB exposure | 27/23 | The diagnosis and treatment scheme for COVID-19 of Chinese (6th edition). | Diabetes(8.0%); Coronary heart disease(2.0%); Chronic obstructive pulmonary disease(2.0%); Anemia (2.0%) | ACEI/ARB vs Non-ACEI/ARB | Severity and death risk | Moderate |

| | | | | | | | | 64 (55-68) for | | New Coronavirus Pneumonia | | | | |
|------------|------|--------|-------|----------------------|-------|-------------|-----|---------------------------------------------------------|-------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-------------------------|--------|
| | | | | | | | | ACEI/ARB | | Prevention and Control | Hypertension (100%); Diabetes (n=244); Coronary heart | | | |
| Zhang P | 2020 | China | Asian | Retrospective | 1128 | 118 | 940 | exposure; | 603/525 | Program (5th edition) | disease (n=131); Chronic renal diseases (n=35); | ACEI/ARB vs Non–ACEI/ARB | Death risk | High |
| [22] | 2020 | Ciiiia | Asian | cohort | 1126 | 116 | 940 | 64 (57-69) for | | published by the National | Cerebrovascular diseases (n=41); Chronic liver disease | ACEI/ARD VS NOII-ACEI/ARD | Death fisk | riigii |
| | | | | | | | | Non-ACEI/ARI | 3 | Health Commission of China | (n=21); Chronic obstructive pulmonary disease (n=6) | | | |
| | | | | | | | | exposure | | and WHO interim guidance | | | | |
| | | | | | | | | 65 (57-72) for | | | | | | |
| Yang G [8] | 2020 | China | Asian | Retrospective cohort | 126 | 43 | 83 | ACEI/ARB exposure; 67 (62-75) for non-ACEI/ARE exposure | | The Fifth Trial Version of the Chinese National Health Commission | Hypertension (100%); Diabetes (30.2%); Respiratory disease (4.7%); Kidney disease (2.4%); Hepatic disease (6.3%); Cardiopathy (18.3%); Neurological disease (7.9%) | ACEI/ARB vs Non–ACEI/ARB | Severity and death risk | High |
| | | | | | | | | | | Positive nasopharyngeal swab | | | | |
| | | | | | | | | | | specimens tested with at least | | | | |
| Mancia G | | | | | | 8071 for | | | | two real-time | Cardiovascular disease (23.1%); Respiratory disease (6.4%); | ACEI vs Non–ACEI; | | |
| [10] | 2020 | Italy | NA | Case-control | 37031 | ACEI; | NA | NA | 23371/13660 | reverse-transcriptase- | Kidney disease (3.0%); Cancer (15.5%) | ARB vs Non-ARB; | Infection risk | High |
| | | | | | 7 | 304 for ARB | | | | polymerase-chain-reaction | | | | |
| | | | | | | | | | | assays targeting different | | | | |
| | | | | | | | | | | genes of SARSCov-2. | | | | |

| Reynolds HR [23] | 2020 | United States | Mixed | Retrospective cohort | AC 1328 12,594 AF 2319 | 4 for EEI; 8 for RB; 9 for or ARB | NA | 49 (34–63) | 5229/7365 | A series of SARS-CoV-2 RNA test | Hypertension (34.6%); Heart failure (6.2%); myocardial infarction (4.2%); Diabetes (18.0%); Chronic kidney disease (9.6%); Obstructive lung disease (14.6%) | ACEI vs Non-ACEI; ARB vs Non-ARB; ACEI/ARB vs Non-ACEI/ARB | Infection risk | High |
|---------------------|------|------------------|-------|----------------------|--------------------------------------------|-----------------------------------|----|---------------------|-----------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|------------------------------------|----------|
| Feng Y | 2020 | China | Asian | Retrospective cohort | 8 for A 27 for 476 33 for or A | ARB; | NA | 53(40-64) | 271/205 | The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition). | Hypertension (23.7%); Cardiovascular disease (8.0%); Diabetes (10.3%); Malignancy (2.5%); Cerebrovascular disease (3.6%); Immunosuppression (1.5%); COPD (4.6%); Chronic nephropathy (0.8%); Others (21.6%) | ACEI vs Non-ACEI; ARB vs Non-ARB; ACEI/ARB vs Non-ACEI/ARB | Severity risk | Moderate |
| Meng J [25] | 2020 | China | Asian | Retrospective cohort | 42 1 | 7 | 25 | 64.5 (55.8–69.0) | 24/18 | The guidelines established by the National Health Commission of the People's Republic of China. | Hypertension (100%); other comorbidities (not reported) | ACEI/ARB vs Non–ACEI/ARB | Death risk | Moderate |
| de Abajo FJ [26] | 2020 | Spain | NA | Case-control | 2433 12529 AC 1860 fc | | NA | 75.3±12.3 | 7645/4884 | a PCR-confirmed diagnosis of COVID-19 | Hypertension (50.0%); Diabetes (20.9%); Dyslipidaemia (31.7%); Ischaemic heart disease (7.8%); Heart failure (3.8%); Atrial fibrillation (8.8%); Thromboembolic disease (2.7%); Cerebrovascular accident (5.1%); COPD (8.3%); Asthma (5.7%); Cancer (14.2%); Chronic renal failure (5.3%) | ACEI vs Non-ACEI; ARB vs Non-ARB | Infection risk | High |
| Zeng Z | 2020 | China | Asian | Retrospective | 75 2 | 8 | 47 | 67±11 | 35/40 | the criteria of COVID-19 previously established by the WHO | Hypertension (100%) | ACEI/ARB vs Non–ACEI/ARB | Infection, severity and death risk | Moderate |

| Bean DM | 2020 | United Kingdom | Mixed | Retrospective cohort | 1200 | 399 | 801 | 67.96 ±17.07 | 686/514 | NA | Hypertension (53.8%); Diabetes(34.8%); HF(8.9%); IHD(13.3%); COPD(10.1%); Asthma(14.1%); CKD(17.2%); Stroke/TIA(19.6%) | ACEI/ARB vs Non-ACEI/ARB | Death risk | High |
|----------------------------|------|-------------------|-------|-------------------------|-------|--------------------------------------------------------------|---------------------------------------------------------------------------------|------------------|-----------|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-----------------------------------------|----------|
| Rentsch CT[29] | 2020 | United States | Mixed | Retrospective cohort | | 1011 for ACEI; 563 for ARB; 1532 for ACEI or ARB | 2778 for Non-ACEI; 3226 for Non-ARB; 2257 for Non-ACEI or ARB | 65.7 (60.5-70.7) | 3417/372 | PCR tested positive for SARS-CoV-2 | Asthma (7.5%); Cancer(15.1%); Chronic kidney disease (14.8%); COPD(26.2%); Diabetes (32.8%); Hypertension (65.0%); Liver disease (12.3%); Vascular disease (28.9%) | ACEI/ARB vs Non–ACEI/ARB | Infection, Hospitalization and ICU risk | High |
| Giorgi Rossi P[30] | 2020 | Italy | NA | Retrospective | 2653 | NA | NA | All age group | 1328/1325 | all symptomatic patients who tested positive with PCR | NA | ACEI vs Non-ACEI | Hospitalization and death | High |
| De Spiegeleer A [31] | 2020 | Belgium | NA | Retrospective | 154 | 30 | 124 | 86±7 | 51/103 | clinical grounds and/or PCR | Hypertension (25.3%); Diabetes(18.2%) | ACEI/ARB vs Non-ACEI/ARB | Infection and severity | High |
| Khera R | 2020 | United States | Mixed | Retrospective | 10196 | 3083 for ACEI; 2957 for ARB | NA | ≥18 | 4675/5521 | PCR tested positive for SARS-CoV-2 | Hypertension (100%) | ACEI vs Others; ARB vs Others; ACEI vs ARB | Hospitalization and death | High |
| Liu Y [33] | 2020 | China | Asian | Retrospective | 46 | 2 for ACEI; 10 for ARB | NA | >65 | NA | The diagnosis and treatment scheme for COVID-19 of Chinese | Hypertension (100%) | ACEI vs Non-ACEI; ARB vs Non-ARB | Severity risk | Moderate |

| Richardson S [34] | 2020 | United States | Mixed | Retrospective | | 168 for ACEI; 245 for ARB; 413 for ACEI or ARB | 953 | 63(52-75) | 3437/2263 | PCR tested positive for SARS-CoV-2 | Hypertension (56.6%); Coronary artery disease(11.1%); COPD(5.4%); Cancer (6%) | ACEI/ARB vs Non-ACEI/ARB | Death risk | High |
|----------------------|------|------------------|-------|---------------|--------|------------------------------------------------------------|-------------------------------|-------------|-------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------|----------|
| Guo T [35] | 2020 | China | Asian | Retrospective | 187 | 19 for ACEI or ARB | 168 for Non-ACEI or ARB | 58.50±14.66 | 91/96 | The interim guidance of the World Health Organization | Hypertension (32.6%); CHD (11.2%); Cardiomyopathy(4.3%); Diabetes(15.0%); COPD (2.1%); Malignant neoplasm (7.0%); Chronic kidney disease (3.2%) | ACEI/ARB vs Non–ACEI/ARB | Death risk | High |
| Yan H [36] | 2020 | China | Asian | Case-control | 49,277 | 5for ACEI; 53 for ARB; 58 for ACEI or ARB | NA | 48.75±14.19 | 23817/25460 | The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition). | Diabetes(6.14%); Hypertension (20.28%); Cardio or cerebrovascular disease (1.3%); Tumour (2.0%) | ACEI vs Non–ACEI; ARB vs Non–ARB | Infection and severity risk | High |
| Andrew Ip | 2020 | United States | NA | Retrospective | 1129 | 460 for ACEI or ARB | 669 for Non-ACEI or ARB | NA | NA | NA | Hypertension (100%) | ACEI/ARB vs Non-ACEI/ARB | Death risk | Moderate |

Table 2. Meta-analysis on the association between ACEI/ARB use and risk of infection, hospital admission, severity, and death of COVID-19.

| Subgroup | Number of studies | Crude OR | 95% | %CI | P | I2(%) | Model | Number of studies | Adjusted OR | 959 | %CI | P | I2(%) | Model |
|-----------------|-------------------------|-------------|------|------|---------|-------|-------|-------------------|----------------|------|------|-------|-------|-------|
| Subgroup Analy | sis for Risk | of Infect | ion | | | | | | | | | | | |
| ACEI use vs noi | n-ACEI use | | | | | | | | | | | | | |
| Overall | 4 | 1.27 | 0.95 | 1.69 | 0.103 | 91.9 | R | 4 | 0.94 | 0.87 | 1.01 | 0.106 | 0 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | 2 | 1.16 | 1.08 | 1.24 | < 0.001 | 12.2 | F | 2 | 0.96 | 0.86 | 1.06 | 0.381 | 0 | F |
| Cohort | 2 | 1.44 | 0.92 | 2.24 | 0.108 | 93.0 | R | 2 | 0.91 | 0.8 | 1.03 | 0.139 | 0 | F |
| Region | | | | | | | | | | | | | | |
| China | 1 | 0.72 | 0.3 | 1.72 | 0.461 | NA | NA | 1 | 0.65 | 0.27 | 1.6 | 0.348 | NA | NA |
| Italy | 1 | 1.16 | 1.08 | 1.24 | < 0.001 | NA | NA | 1 | 0.96 | 0.87 | 1.07 | 0.439 | NA | NA |
| United States | 2 | 1.44 | 0.92 | 2.24 | 0.108 | 93.0 | R | 2 | 0.91 | 0.8 | 1.03 | 0.139 | 0 | F |
| Race | | | | | | | | | | | | | | |
| Asian | 1 | 0.72 | 0.3 | 1.72 | 0.461 | NA | NA | 1 | 0.65 | 0.27 | 1.6 | 0.348 | NA | NA |
| Mixed | 2 | 1.44 | 0.92 | 2.24 | 0.108 | 93.0 | R | 2 | 0.91 | 0.8 | 1.03 | 0.139 | 0 | F |
| Unknown | 1 | 1.16 | 1.08 | 1.24 | < 0.001 | NA | NA | 1 | 0.96 | 0.87 | 1.07 | 0.439 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 4 | 1.27 | 0.95 | 1.69 | 0.103 | 91.9 | R | 3 | 0.94 | 0.87 | 1.03 | 0.192 | 0 | F |
| Moderate | 0 | NA | NA | NA | NA | NA | NA | 1 | 0.89 | 0.72 | 1.10 | 0.281 | NA | NA |
| ARB use vs non- | -ARB use | | | | | | | | | | | | | |
| Overall | 4 | 1.07 | 0.76 | 1.50 | 0.709 | 95.7 | R | 4 | 0.73 | 0.49 | 1.09 | 0.120 | 95.1 | R |

| $\boldsymbol{\neg}$ | $\boldsymbol{\gamma}$ |
|---------------------|-----------------------|
| 4 | • |
| | |

| Study design | | | | | | | | | | | | | | |
|-----------------|-----------|----------|------|------|---------|------|----|---|------|------|-------|---------|------|----|
| Case-control | 2 | 0.80 | 0.35 | 1.81 | 0.59 | 97.0 | R | 2 | 0.48 | 0.13 | 1.86 | 0.289 | 98.2 | R |
| Cohort | 2 | 1.40 | 0.93 | 2.10 | 0.107 | 89.5 | R | 2 | 1.03 | 0.91 | 1.16 | 0.688 | 0 | F |
| Region | | | | | | | | | | | | | | |
| China | 1 | 0.52 | 0.40 | 0.68 | < 0.001 | NA | NA | 1 | 0.24 | 0.17 | 0.34 | < 0.001 | NA | NA |
| Italy | 1 | 1.20 | 1.12 | 1.29 | < 0.001 | NA | NA | 1 | 0.95 | 0.86 | 1.05 | 0.314 | NA | NA |
| United States | 2 | 1.40 | 0.93 | 2.10 | 0.107 | 89.5 | R | 2 | 1.03 | 0.91 | 1.16 | 0.688 | 0 | F |
| Race | | | | | | | | | | | | | | |
| Asian | 1 | 0.52 | 0.40 | 0.68 | < 0.001 | NA | NA | 1 | 0.24 | 0.17 | 0.34 | < 0.001 | NA | NA |
| Mixed | 2 | 1.40 | 0.93 | 2.10 | 0.107 | 89.5 | R | 2 | 1.03 | 0.91 | 1.16 | 0.688 | 0 | F |
| Unknown | 1 | 1.20 | 1.12 | 1.29 | < 0.001 | NA | NA | 1 | 0.95 | 0.86 | 1.05 | 0.314 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 4 | 1.07 | 0.76 | 1.50 | 0.709 | 95.7 | R | 3 | 0.64 | 0.38 | 1.06 | 0.083 | 96.6 | R |
| Moderate | 0 | NA | NA | NA | NA | NA | NA | 1 | 1.09 | 0.87 | 1.37 | 0.457 | NA | NA |
| ACEI/ARB use vs | s non-ACI | EI/ARB u | se | | | | | | | | | | | |
| Overall | 7 | 1.10 | 0.84 | 1.43 | 0.488 | 88.6 | R | 6 | 0.96 | 0.91 | 1.01 | 0.142 | 5.8 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | 2 | 0.81 | 0.38 | 1.74 | 0.583 | 97.0 | R | 2 | 0.66 | 0.26 | 1.68 | 0.387 | 75.3 | R |
| Cohort | 5 | 1.31 | 0.96 | 1.77 | 0.089 | 71.8 | R | 3 | 0.97 | 0.89 | 1.05 | 0.425 | 0 | F |
| Region | | | | | | | | | | | | | | |
| China | 3 | 0.75 | 0.47 | 1.21 | 0.241 | 70.2 | R | 1 | 0.36 | 0.14 | 0.93 | 0.035 | NA | NA |
| United States | 2 | 1.46 | 0.93 | 2.29 | 0.096 | 90.3 | R | 2 | 0.97 | 0.89 | 1.05 | 0.398 | 0 | F |
| Belgium | 1 | 1.52 | 0.64 | 3.61 | 0.343 | NA | NA | 1 | 2.72 | 0.42 | 17.74 | 0.296 | NA | NA |

| 34 |
|----|
|----|

| Italy | 1 | 1.18 | 1.12 | 1.24 | < 0.001 | NA | NA | 1 | 0.96 | 0.89 | 1.03 | 0.273 | NA | NA |
|------------------|-------------|----------|----------|---------|---------|------|----|---|------|------|------|-------|------|----|
| Race | | | | | | | | | | | | | | |
| Asian | 3 | 0.75 | 0.47 | 1.21 | 0.241 | 70.2 | R | 1 | 0.36 | 0.14 | 0.93 | 0.035 | NA | NA |
| Mixed | 2 | 1.46 | 0.93 | 2.29 | 0.096 | 90.3 | R | 4 | 0.97 | 0.89 | 1.05 | 0.425 | 0 | F |
| Unknown | 2 | 1.18 | 1.12 | 1.24 | < 0.001 | 0 | F | 1 | 0.96 | 0.89 | 1.03 | 0.273 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 6 | 1.1 | 0.83 | 1.44 | 0.515 | 90.5 | R | 5 | 0.96 | 0.91 | 1.02 | 0.152 | 24.4 | F |
| Moderate | 1 | 1.15 | 0.39 | 3.37 | 0.799 | NA | NA | 1 | 0.97 | 0.81 | 1.16 | 0.733 | NA | NA |
| Subgroup Analys | is for Risk | of Hospi | ital Adn | nission | | | | | | | | | | |
| ACEI use vs non- | ACEI use | | | | | | | | | | | | | |
| Overall | NA | NA | NA | NA | NA | NA | NA | 3 | 1.29 | 1.07 | 1.57 | 0.009 | 62.4 | R |
| Study design | | | | | | | | | | | | | | |
| Case-control | NA | NA | NA | NA | NA | NA | NA | 1 | 1.13 | 0.97 | 1.31 | 0.111 | NA | NA |
| Cohort | NA | NA | NA | NA | NA | NA | NA | 2 | 1.46 | 1.06 | 2.02 | 0.021 | 57.9 | R |
| Region | | | | | | | | | | | | | | |
| Italy | NA | NA | NA | NA | NA | NA | NA | 1 | 1.30 | 1.11 | 1.52 | 0.001 | NA | NA |
| United States | NA | NA | NA | NA | NA | NA | NA | 1 | 1.84 | 1.22 | 2.78 | 0.004 | NA | NA |
| Spain | NA | NA | NA | NA | NA | NA | NA | 1 | 1.13 | 0.97 | 1.31 | 0.111 | NA | NA |
| Race | | | | | | | | | | | | | | |
| Mixed | NA | NA | NA | NA | NA | NA | NA | 1 | 1.84 | 1.22 | 2.78 | 0.004 | NA | NA |
| Unknown | NA | NA | NA | NA | NA | NA | NA | 2 | 1.21 | 1.09 | 1.35 | 0.001 | 38.2 | F |
| Quality | | | | | | | | | | | | | | |
| High | NA | NA | NA | NA | NA | NA | NA | 2 | 1.21 | 1.09 | 1.35 | 0.001 | 38.2 | F |
| | | | | | | | | | | | | | | |

| 2 | 5 |
|---|---|
| J | J |

| Moderate | NA | NA | NA | NA | NA | NA | NA | 1 | 1.84 | 1.22 | 2.78 | 0.004 | NA | NA |
|------------------|-----------|----------|----|----|----|----|----|---|------|------|------|---------|------|----|
| ARB use vs non-A | ARB use | | | | | | | | | | | | | |
| Overall | NA | NA | NA | NA | NA | NA | NA | 2 | 1.69 | 1.46 | 1.96 | < 0.001 | 0 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | NA | NA | NA | NA | NA | NA | NA | 1 | 1.70 | 1.46 | 1.99 | < 0.001 | NA | NA |
| Cohort | NA | NA | NA | NA | NA | NA | NA | 1 | 1.61 | 1.04 | 2.50 | 0.033 | NA | NA |
| Region | | | | | | | | | | | | | | |
| United States | NA | NA | NA | NA | NA | NA | NA | 1 | 1.61 | 1.04 | 2.50 | 0.033 | NA | NA |
| Spain | NA | NA | NA | NA | NA | NA | NA | 1 | 1.70 | 1.46 | 1.99 | < 0.001 | NA | NA |
| Race | | | | | | | | | | | | | | |
| Mixed | NA | NA | NA | NA | NA | NA | NA | 1 | 1.61 | 1.04 | 2.50 | 0.033 | NA | NA |
| Unknown | NA | NA | NA | NA | NA | NA | NA | 1 | 1.70 | 1.46 | 1.99 | < 0.001 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | NA | NA | NA | NA | NA | NA | NA | 1 | 1.70 | 1.46 | 1.99 | < 0.001 | NA | NA |
| Moderate | NA | NA | NA | NA | NA | NA | NA | 1 | 1.61 | 1.04 | 2.5 | 0.033 | NA | NA |
| ACEI/ARB use vs | s non-ACI | EI/ARB u | se | | | | | | | | | | | |
| Overall | NA | NA | NA | NA | NA | NA | NA | 4 | 1.38 | 1.21 | 1.57 | < 0.001 | 34.5 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | NA | NA | NA | NA | NA | NA | NA | 1 | 1.39 | 0.93 | 2.07 | 0.107 | NA | NA |
| Cohort | NA | NA | NA | NA | NA | NA | NA | 3 | 1.45 | 1.11 | 1.88 | 0.006 | 56.3 | R |
| Region | | | | | | | | | | | | | | |
| United States | NA | NA | NA | NA | NA | NA | NA | 2 | 1.59 | 1.03 | 2.44 | 0.035 | 57.7 | R |
| Spain | NA | NA | NA | NA | NA | NA | NA | 1 | 1.39 | 0.93 | 2.07 | 0.107 | NA | NA |

| $^{\circ}$ | _ |
|------------|---|
| | n |
| | |

| Italy | NA | NA | NA | NA | NA | NA | NA | 1 | 1.30 | 1.11 | 1.52 | 0.001 | NA | NA |
|------------------|-------------|----------|------|------|-------|------|----|---|------|------|------|---------|------|----|
| Race | | | | | | | | | | | | | | |
| Mixed | NA | NA | NA | NA | NA | NA | NA | 2 | 1.59 | 1.03 | 2.44 | 0.035 | 57.7 | R |
| Unknown | NA | NA | NA | NA | NA | NA | NA | 2 | 1.31 | 1.14 | 1.52 | < 0.001 | 0 | F |
| Quality | | | | | | | | | | | | | | |
| High | NA | NA | NA | NA | NA | NA | NA | 3 | 1.31 | 1.14 | 1.50 | < 0.001 | 0 | F |
| Moderate | NA | NA | NA | NA | NA | NA | NA | 1 | 1.93 | 1.38 | 2.71 | < 0.001 | NA | NA |
| Subgroup Analys | is for Risk | of Sever | ity | | | | | | | | | | | |
| ACEI use vs non- | ACEI use | | | | | | | | | | | | | |
| Overall | 5 | 1.01 | 0.63 | 1.60 | 0.982 | 75.3 | R | 2 | 0.90 | 0.72 | 1.14 | 0.939 | 0 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | 1 | 0.91 | 0.69 | 1.21 | 0.510 | NA | NA | 1 | 0.90 | 0.71 | 1.14 | 0.374 | NA | NA |
| Cohort | 4 | 0.99 | 0.51 | 1.90 | 0.964 | 60.7 | R | 1 | 1.23 | 0.19 | 7.95 | 0.828 | NA | NA |
| Region | | | | | | | | | | | | | | |
| China | 3 | 0.73 | 0.40 | 1.33 | 0.308 | 0 | F | 1 | 1.23 | 0.19 | 7.95 | 0.828 | NA | NA |
| Italy | 1 | 0.91 | 0.69 | 1.21 | 0.510 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| United States | 1 | 1.63 | 1.34 | 1.99 | 0.001 | NA | NA | 1 | 0.90 | 0.71 | 1.14 | 0.374 | NA | NA |
| Race | | | | | | | | | | | | | | |
| Asian | 3 | 0.73 | 0.4 | 1.33 | 0.308 | 0 | F | 1 | 1.23 | 0.19 | 7.95 | 0.828 | NA | NA |
| Mixed | 1 | 1.63 | 1.34 | 1.99 | 0.001 | NA | NA | 1 | 0.90 | 0.71 | 1.14 | 0.374 | NA | NA |
| Unknown | 1 | 0.91 | 0.69 | 1.21 | 0.510 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| Quality | | | | | | | | | | | | | | |

| $^{-}$ | ~ |
|--------|---|
| • | |
| | |

| High | 2 | 1.34 | 1.14 | 1.58 | < 0.001 | 91.0 | R | 2 | 0.90 | 0.72 | 1.14 | 0.939 | 0 | F |
|------------------|-----------|----------|------|------|---------|------|----|---|------|------|------|-------|------|----|
| _ | | | | | | | | | | | | | | |
| Moderate | 3 | 0.73 | 0.4 | 1.33 | 0.308 | 0 | F | 0 | NA | NA | NA | NA | NA | NA |
| ARB use vs non-A | ARB use | | | | | | | | | | | | | |
| Overall | 5 | 0.75 | 0.41 | 1.39 | 0.090 | 91.8 | R | 3 | 0.91 | 0.74 | 1.13 | 0.409 | 45.8 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | 1 | 0.83 | 0.63 | 1.10 | 0.190 | NA | NA | 1 | 0.77 | 0.36 | 1.64 | 0.498 | NA | NA |
| Cohort | 4 | 0.70 | 0.29 | 1.69 | 0.427 | 91.8 | R | 2 | 0.59 | 0.17 | 2.09 | 0.413 | 71.2 | R |
| Region | | | | | | | | | | | | | | |
| China | 3 | 0.48 | 0.16 | 1.50 | 0.206 | 86.9 | R | 2 | 0.60 | 0.31 | 1.16 | 0.723 | NA | NA |
| Italy | 1 | 0.83 | 0.63 | 1.10 | 0.190 | NA | NA | 1 | 0.96 | 0.77 | 1.20 | 0.128 | 48.1 | F |
| United States | 1 | 1.76 | 1.47 | 2.10 | < 0.001 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| Race | | | | | | | | | | | | | | |
| Asian | 3 | 0.48 | 0.16 | 1.50 | 0.206 | 86.9 | R | 2 | 0.60 | 0.31 | 1.16 | 0.723 | NA | NA |
| Mixed | 1 | 1.76 | 1.47 | 2.10 | < 0.001 | NA | NA | 1 | 0.96 | 0.77 | 1.20 | 0.128 | 48.1 | F |
| Unknown | 1 | 0.83 | 0.63 | 1.10 | 0.190 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 2 | 1.22 | 0.58 | 2.54 | 0.599 | 95.0 | R | 2 | 0.94 | 0.76 | 1.17 | 0.594 | 0 | F |
| Moderate | 3 | 0.48 | 0.16 | 1.50 | 0.206 | 86.9 | R | 1 | 0.25 | 0.06 | 1.01 | 0.052 | NA | NA |
| ACEI/ARB use vs | s non-ACE | EI/ARB u | se | | | | | | | | | | | |
| Overall | 11 | 0.75 | 0.48 | 1.17 | 0.201 | 88.7 | R | 4 | 0.9 | 0.77 | 1.05 | 0.197 | 27.6 | F |
| Study design | | | | | | | | | | | | | | |
| Case-control | 1 | 0.87 | 0.71 | 1.06 | 0.173 | NA | NA | 1 | 0.82 | 0.41 | 1.65 | 0.578 | NA | NA |
| Cohort | 10 | 0.72 | 0.41 | 1.27 | 0.255 | 87.0 | R | 3 | 0.62 | 0.27 | 1.38 | 0.239 | 50.8 | R |

| 7 | o |
|---|---|
| ٦ | Λ |

| Region | | | | | | | | | | | | | | |
|------------------|-------------|------------|------|------|---------|------|----|---|------|------|------|---------|------|----|
| China | 8 | 0.61 | 0.34 | 1.09 | 0.093 | 73.8 | R | 2 | 0.53 | 0.17 | 1.63 | 0.269 | 55.0 | R |
| United States | 1 | 1.87 | 1.62 | 2.16 | < 0.001 | NA | NA | 1 | 0.93 | 0.79 | 1.09 | 0.377 | NA | NA |
| Belgium | 1 | 0.79 | 0.29 | 2.16 | 0.647 | NA | NA | 1 | 0.48 | 0.11 | 2.13 | 0.334 | NA | NA |
| Italy | 1 | 0.87 | 0.71 | 1.06 | 0.173 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| Race | | | | | | | | | | | | | | |
| Asian | 8 | 0.61 | 0.34 | 1.09 | 0.093 | 73.8 | R | 2 | 0.53 | 0.17 | 1.63 | 0.269 | 55.0 | R |
| Mixed | 1 | 1.87 | 1.62 | 2.16 | < 0.001 | NA | NA | 1 | 0.93 | 0.79 | 1.09 | 0.377 | NA | NA |
| Unknown | 2 | 0.87 | 0.71 | 1.06 | 0.154 | 0 | F | 1 | 0.48 | 0.11 | 2.13 | 0.334 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 4 | 1.05 | 0.59 | 1.88 | 0.860 | 92.6 | R | 3 | 0.92 | 0.79 | 1.07 | 0.279 | 0 | F |
| Moderate | 7 | 0.59 | 0.30 | 1.17 | 0.129 | 77.5 | R | 1 | 0.25 | 0.06 | 1.01 | 0.052 | NA | NA |
| Subgroup Analysi | is for Risl | k of Death | 1 | | | | | | | | | | | |
| ACEI use vs non- | ACEI use | ! | | | | | | | | | | | | |
| Overall | 2 | 0.51 | 0.19 | 1.38 | 0.185 | 74.6 | R | 2 | 0.52 | 0.15 | 1.82 | 0.307 | 93.8 | R |
| Study design | | | | | | | | | | | | | | |
| Case-control | 0 | NA | NA | NA | NA | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| Cohort | 2 | 0.51 | 0.19 | 1.38 | 0.185 | 74.6 | R | 2 | 0.52 | 0.15 | 1.82 | 0.307 | 93.8 | R |
| Region | | | | | | | | | | | | | | |
| China | 1 | 0.91 | 0.38 | 2.18 | 0.832 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| Italy | 0 | NA | NA | NA | NA | NA | NA | 1 | 0.97 | 0.70 | 1.35 | 0.857 | NA | NA |
| Multiple areas | 1 | 0.33 | 0.20 | 0.54 | < 0.001 | NA | NA | 1 | 0.27 | 0.16 | 0.46 | < 0.001 | NA | NA |
| Race | | | | | | | | | | | | | | |


| $\boldsymbol{\neg}$ | $^{\circ}$ |
|---------------------|------------|
| 4 | ч |
| | |

| Asian | 1 | 0.91 | 0.38 | 2.18 | 0.832 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
|------------------|-----------|----------|------|------|---------|------|----|----|------|------|------|---------|------|----|
| Mixed | 1 | 0.33 | 0.20 | 0.54 | < 0.001 | NA | NA | 1 | 0.27 | 0.16 | 0.46 | < 0.001 | NA | NA |
| Unknown | 0 | NA | NA | NA | NA | NA | NA | 1 | 0.97 | 0.70 | 1.35 | 0.857 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 1 | 0.33 | 0.20 | 0.54 | < 0.001 | NA | NA | 2 | 0.52 | 0.15 | 1.82 | 0.307 | 93.8 | R |
| Moderate | 1 | 0.91 | 0.38 | 2.18 | 0.832 | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
| ARB use vs non-A | ARB use | | | | | | | | | | | | | |
| Overall | 2 | 1.1 | 0.81 | 1.49 | 0.531 | 39.5 | F | NA | NA | NA | NA | NA | NA | NA |
| Study design | | | | | | | | | | | | | | |
| Case-control | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Cohort | 2 | 1.1 | 0.81 | 1.49 | 0.531 | 39.5 | F | NA | NA | NA | NA | NA | NA | NA |
| Region | | | | | | | | | | | | | | |
| China | 1 | 0.77 | 0.41 | 1.44 | 0.412 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Multiple areas | 1 | 1.23 | 0.87 | 1.74 | 0.242 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Race | | | | | | | | | | | | | | |
| Asian | 1 | 0.77 | 0.41 | 1.44 | 0.412 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Mixed | 1 | 1.23 | 0.87 | 1.74 | 0.242 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 1 | 1.23 | 0.87 | 1.74 | 0.242 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Moderate | 1 | 0.77 | 0.41 | 1.44 | 0.412 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| ACEI/ARB use vs | s non-ACI | EI/ARB u | se | | | | | | | | | | | |
| Overall | 11 | 0.87 | 0.66 | 1.15 | 0.322 | 57.0 | R | 5 | 0.51 | 0.31 | 0.84 | 0.009 | 78.4 | R |
| Study design | | | | | | | | | | | | | | |

| Case-control | 0 | NA | NA | NA | NA | NA | NA | 0 | NA | NA | NA | NA | NA | NA |
|----------------|----|------|------|------|-------|------|----|---|------|------|------|---------|------|----|
| Cohort | 11 | 0.87 | 0.66 | 1.15 | 0.322 | 57.0 | R | 5 | 0.51 | 0.31 | 0.84 | 0.009 | 78.4 | R |
| Region | | | | | | | | | | | | | | |
| China | 6 | 0.74 | 0.42 | 1.30 | 0.299 | 32.5 | F | 2 | 0.36 | 0.17 | 0.77 | 0.009 | 0 | F |
| United States | 3 | 1.05 | 0.61 | 1.82 | 0.866 | 85.6 | R | 0 | NA | NA | NA | NA | NA | NA |
| United Kingdom | 1 | 0.83 | 0.64 | 1.07 | 0.155 | NA | NA | 1 | 0.63 | 0.47 | 0.84 | 0.002 | NA | NA |
| Multiple areas | 1 | 0.65 | 0.18 | 2.34 | 0.510 | NA | NA | 1 | 0.27 | 0.16 | 0.46 | < 0.001 | NA | NA |
| Italy | 0 | NA | NA | NA | NA | NA | NA | 1 | 0.97 | 0.70 | 1.35 | 0.857 | NA | NA |
| Race | | | | | | | | | | | | | | |
| Asian | 6 | 0.74 | 0.42 | 1.30 | 0.299 | 32.5 | F | 2 | 0.36 | 0.17 | 0.77 | 0.009 | 0 | F |
| Mixed | 4 | 1.06 | 0.76 | 1.50 | 0.719 | 56.9 | R | 2 | 0.43 | 0.19 | 0.97 | 0.043 | 86.8 | R |
| Unknown | 1 | 0.66 | 0.51 | 0.86 | 0.002 | NA | NA | 1 | 0.97 | 0.70 | 1.35 | 0.857 | NA | NA |
| Quality | | | | | | | | | | | | | | |
| High | 5 | 0.88 | 0.59 | 1.34 | 0.571 | 75.9 | R | 5 | 0.51 | 0.31 | 0.84 | 0.009 | 78.4 | R |
| Moderate | 6 | 0.73 | 0.59 | 0.92 | 0.006 | 23.9 | F | 0 | NA | NA | NA | NA | NA | NA |

Records identified from five

electronic database (n=471)



22 articles were included for systematic review and meta-analysis

Records identified through

other sources (n=6)



| | | | | Odds Ratio | | Odd | ls Ratio |) | |
|-------------------------------------------------------------------|-----------------|-----------|------------|------------------|--------------|-------------------------|----------------|-----------------|-----|
| Study or Subgroup | log[Odds Ratio] | SE | Weight | IV, Random, 95% | CI | IV, Rand | <u>dom, 95</u> | 5% CI | |
| Mancia G 2020 | 0.148 | 0.035 | 32.3% | 1.16 [1.08, 1.2 | 4] | | | | |
| Rentsch CT 2020 | 0.582 | 0.065 | 30.9% | 1.79 [1.58, 2.0 | 3] | | • | | |
| Reynolds HR 2020 | 0.131 | 0.1 | 28.6% | 1.14 [0.94, 1.3 | 9] | | • | | |
| Yan H 2020 | -0.329 | 0.445 | 8.2% | 0.72 [0.30, 1.7 | 2] | _ | • | | |
| Total (95% CI) | | | 100.0% | 1.27 [0.95, 1.69 | 9] | | • | ı | |
| Heterogeneity: Tau ² = 0 Test for overall effect: Z | | df = 3 (I | P < 0.0000 | 01); I² = 92% | 0.0 Favou | 1 0.1 rs experimenta | 1 I Favo | 10 ours cont | 100 |


В

| Study or Subgroup | log[Odds Ratio] | SE | Weight | Odds Ratio IV, Random, 95% C | l | | lds Ratio | | |
|-------------------------------------------------------------------|-----------------|-----------|------------|---------------------------------|------------------|-------------------|--------------|-----------------|------------|
| Mancia G 2020 | 0.182 | 0.036 | 26.8% | 1.20 [1.12, 1.29] | | | | | |
| Rentsch CT 2020 | 0.531 | 0.058 | 26.3% | 1.70 [1.52, 1.91] | | | | | |
| Reynolds HR 2020 | 0.113 | 0.122 | 23.9% | 1.12 [0.88, 1.42] | | | * | | |
| Yan H 2020 | -0.654 | 0.139 | 23.1% | 0.52 [0.40, 0.68] | | 7 | • | | |
| Total (95% CI) | | | 100.0% | 1.07 [0.76, 1.50] | | 1 | * | ı | ı |
| Heterogeneity: Tau ² = 0 Test for overall effect: 2 | | df = 3 (I | P < 0.0000 | • | 0.01 avours e | 0.1 experiment | 1 al Favo | 10 ours cont | 100 rol |

C

| | | | Odds Ratio | Odds Ratio | |
|---------------------------------------|--------------------------------|------------------|--------------------|---------------------------------------------------|-----|
| Study or Subgroup | log[Odds Ratio] | SE Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| De Spiegeleer A 2020 | 0.419 0.44 | 42 6.4% | 1.52 [0.64, 3.62] | +- | |
| Mancia G 2020 | 0.166 0.03 | 26 20.5% | 1.18 [1.12, 1.24] | • | |
| Rentsch CT 2020 | 0.157 0.08 | 89 18.9% | 1.17 [0.98, 1.39] | • | |
| Reynolds HR 2020 | 0.615 0.1 | 12 18.0% | 1.85 [1.49, 2.30] | - | |
| Yan H 2020 | -0.616 0.13 | 33 17.1% | 0.54 [0.42, 0.70] | * | |
| Yang G 2020 | -0.062 0.19 | 92 14.5% | 0.94 [0.65, 1.37] | + | |
| Zeng Z 2020 | 0.14 0.5 | 48 4.6% | 1.15 [0.39, 3.37] | | |
| Total (95% CI) | | 100.0% | 1.10 [0.84, 1.43] | * | |
| Heterogeneity: Tau ² = 0.0 | 09; $Chi^2 = 52.27$, $df = 6$ | $(P < 0.0000)^2$ | 1); l² = 89% |)1 01 1 10 1 | |
| Test for overall effect: Z = | = 0.69 (P = 0.49) | | 0.0 Favor | 01 0.1 1 10 1 urs experimental Favours control | 100 |







E

| | | | | Odds Ratio | Odds Ratio | | | | |
|------------------------------------------------------------|-----------------|-------|--------|-------------------|------------|------------|---------|-----------|-----|
| Study or Subgroup | log[Odds Ratio] | SE | Weight | IV, Random, 95% C | Î | IV, Rar | dom, 9 | 5% CI | |
| Mancia G 2020 | -0.051 | 0.051 | 26.6% | 0.95 [0.86, 1.05] | | | • | | |
| Mehta N 2020 | 0.086 | 0.116 | 24.8% | 1.09 [0.87, 1.37] | | | + | | |
| Reynolds HR 2020 | 0 | 0.074 | 26.1% | 1.00 [0.86, 1.16] | | | • | | |
| Yan H 2020 | -1.427 | 0.177 | 22.4% | 0.24 [0.17, 0.34] | | - | | | |
| Total (95% CI) | | | 100.0% | 0.73 [0.49, 1.08] | | | • | | |
| Heterogeneity: Tau ² = Test for overall effect: | P < 0.0000 | | 0.01 | 0.1 experiment | 1 | 10 | 100 | | |
| | | | | Г | avours t | sypeninent | ai ravo | Juis Cont | IUI |

F

| Study or Subgroup | []pol | SE | Weight | IV, Fixed, 95% (| CI IV, F | ixed, 95% | 6 CI | |
|-----------------------------------------------------------------------------------------------------------------------|--------|-------|--------|--------------------|-------------------|-----------|------------|-----|
| De Spiegeleer A 2020 | 1.001 | 0.957 | 0.1% | 2.72 [0.42, 17.76] |] | - | | |
| Mancia G 2020 | -0.041 | 0.037 | 56.5% | 0.96 [0.89, 1.03] |] | • | | |
| Mehta N 2020 | -0.03 | 0.089 | 9.8% | 0.97 [0.82, 1.16] |] | † | | |
| Rentsch CT 2020 | -0.02 | 0.116 | 5.8% | 0.98 [0.78, 1.23] |] | + | | |
| Reynolds HR 2020 | -0.041 | 0.053 | 27.5% | 0.96 [0.87, 1.06] |] | • | | |
| Yan H 2020 | -1.022 | 0.486 | 0.3% | 0.36 [0.14, 0.93] |] | | | |
| Total (95% CI) | | | 100.0% | 0.96 [0.91, 1.01] | | • | | |
| Heterogeneity: Chi ² = 5.31, df = 5 (P = 0.38); I^2 = 6% Test for overall effect: Z = 1.48 (P = 0.14) | | | | | 0.01 0.1 | 1 | 10 | 100 |
| | | | | | Favours experimen | ıtal Favo | urs contro | ol |






В

| | | Odds Ratio | | Odds Ratio |
|----------------------------------------------------|---------------------------------------------------|------------|--------------------|-----------------------------------|
| Study or Subgroup | log[Odds Ratio] SI | Weight | IV, Random, 95% CI | IV, Random, 95% Cl |
| Feng Y 2020 | -1.427 0.372 | 17.9% | 0.24 [0.12, 0.50] | |
| Li J 2020 | 0.199 0.249 | 20.8% | 1.22 [0.75, 1.99] | - |
| Liu Y 2020 | -1.079 0.499 | 14.9% | 0.34 [0.13, 0.90] | |
| Mancia G 2020 | -0.186 0.142 | 22.9% | 0.83 [0.63, 1.10] | * |
| Reynolds HR 2020 | 0.565 0.09 | 23.5% | 1.76 [1.47, 2.10] | • |
| Total (95% CI) | | 100.0% | 0.75 [0.41, 1.39] | • |
| Heterogeneity: Tau² = 0 Test for overall effect: 2 | 0.41; Chi² = 48.85, df = 4 7 = 0.91 (P = 0.36) | (P < 0.000 | . 0 | .01 0.1 1 10 100 |
| root for overall effect. | 2 0.01 (1 0.00) | | Favo | ours experimental Favours control |

\mathbf{C}

| Study or Subgroup | log[] | SE | Weight | IV, Random, 95% C | IV, Random, 95% CI |
|----------------------------------------------------------------------------------------|-----------|--------|--------|-------------------|--------------------------------------------------------|
| De Spiegeleer A 2020 | -0.236 | 0.514 | 8.2% | 0.79 [0.29, 2.16] | |
| Feng Y 2020 | -1.561 | 0.568 | 7.4% | 0.21 [0.07, 0.64] | |
| Huang Z 2020 | -0.777 | 0.651 | 6.4% | 0.46 [0.13, 1.65] | - |
| Li J 2020 | 0.104 | 0.227 | 13.2% | 1.11 [0.71, 1.73] | - |
| Liu Y 2020 | -0.916 | 0.411 | 9.9% | 0.40 [0.18, 0.90] | |
| Mancia G 2020 | -0.139 | 0.102 | 15.0% | 0.87 [0.71, 1.06] | * |
| Peng YD 2020 | -0.062 | 0.692 | 5.9% | 0.94 [0.24, 3.65] | |
| Reynolds HR 2020 | 0.626 | 0.075 | 15.3% | 1.87 [1.61, 2.17] | • |
| Yang G 2020 | -0.315 | 0.392 | 10.2% | 0.73 [0.34, 1.57] | |
| Zeng Z 2020 | 0.9 | 0.491 | 8.5% | 2.46 [0.94, 6.44] | |
| Total (95% CI) | | | 100.0% | 0.86 [0.57, 1.31] | * |
| Heterogeneity: $Tau^2 = 0.29$; $Chi^2 = 65.51$, $df = 9$ (P < 0.00001); $I^2 = 86\%$ | | | | | 0.04 0.4 4 40 400 |
| Test for overall effect: Z | = 0.68 (P | = 0.50 |) | | 0.01 0.1 1 10 100 Favours experimental Favours control |






E


| | | | | Odds Ratio | | Odds | Ratio | |
|-------------------------------------------------------------------|-----------------|-------|-------------------|-------------------|-----|-----------|-----------|--|
| Study or Subgroup | log[Odds Ratio] | SE W | <u>eight</u> | IV, Fixed, 95% C | | IV, Fixed | l, 95% CI | |
| Liu Y 2020 | -1.386 0.7 | 713 | 2.3% | 0.25 [0.06, 1.01] | | | • | |
| Reynolds HR 2020 | -0.041 0. | 115 8 | 9.7% | 0.96 [0.77, 1.20] | | | | |
| Yan H 2020 | -0.261 0.3 | 385 | 8.0% | 0.77 [0.36, 1.64] | | - | _ | |
| Total (95% CI) | | 10 | 0.0% | 0.91 [0.74, 1.13] | | | | |
| Heterogeneity: Chi ² = 3 Test for overall effect: 2 | Fa | 0.01 | 0.1 1 operimental | 10 Favours co | 100 | | | |


F


| Study or Subgroup | log[] | SE | Weight | IV, Fixed, 95% (| CI IV, Fixed | d, 95% CI | |
|--------------------------------------|------------|----------------------|------------------------------|-------------------|--------------|-----------|--|
| De Spiegeleer A 2020 | -0.734 | 0.76 | 1.1% | 0.48 [0.11, 2.13 |] | | |
| Liu Y 2020 | -1.386 | 0.713 | 1.2% | 0.25 [0.06, 1.01 | | • | |
| Reynolds HR 2020 | -0.073 | 0.082 | 92.8% | 0.93 [0.79, 1.09 |] | | |
| Yan H 2020 | -0.198 | 0.357 | 4.9% | 0.82 [0.41, 1.65 |] | | |
| Total (95% CI) | | | 100.0% | 0.90 [0.77, 1.05] | 1 | | |
| Heterogeneity: Chi ² = 4. | 13, df = 3 | 0.01 0.1 | 1 10 100 | ١ ١ | | | |
| Test for overall effect: Z | = 1.30 (F | Favours experimental | | j | | | |











| L | | | Odds Ratio | Odds Ratio | |
|-------------------------------------|----------------------------------------|--------------------------|--------------------|-----------------------------------|----|
| Study or Subgroup | log[Odds Ratio] SE | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| Bean DM 2020 | -0.462 0.148 | 27.3% | 0.63 [0.47, 0.84] | - | |
| Giorgi Rossi P 2020 | -0.03 0.169 | 26.6% | 0.97 [0.70, 1.35] | * | |
| Mehra MR 2020 | -1.309 0.269 | 22.6% | 0.27 [0.16, 0.46] | - | |
| Yang G 2020 | -1.139 0.784 | 7.9% | 0.32 [0.07, 1.49] | | |
| Zhang P 2020 | -0.994 0.454 | 15.5% | 0.37 [0.15, 0.90] | _ | |
| Total (95% CI) | | 100.0% | 0.51 [0.31, 0.84] | • | |
| Heterogeneity: Tau ² = 0 | 0.22; Chi ² = 18.57, df = 4 | 0); I ² = 78% | 0.01 0.1 1 10 10 | — 00 | |
| Test for overall effect: 2 | Z = 2.62 (P = 0.009) | | - | ours experimental Favours control | 00 |